Crossmark

Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions

Crossref DOI link: https://doi.org/10.1007/s12032-021-01555-1

Published Online: 2021-07-31

Published Print: 2021-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maulhardt, Holly

Marin, Alyson

Hesseltine, Holly

diZerega, Gere https://orcid.org/0000-0002-4150-581X
Funding

Funding for this research was provided by:

NanOlogy, LLC.
License Information

Text and Data Mining valid from 2021-07-31

Version of Record valid from 2021-07-31
More Information

Article History

Received: 1 March 2021

Accepted: 24 July 2021

First Online: 31 July 2021

Declarations

:

: The following authors report holding a consultant/advisory role, having stock ownership or receiving funding from NanOlogy, LLC: H.M., A.M., H.H., and G.S.d.

: All procedures carried out in this experiment were conducted in compliance with the applicable laws, regulations, and guidelines of the National Institutes of Health (NIH) and with the approval of Covance’s Institutional Animal Care and Use Committee (IACUC). Covance is an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited facility.

Document is current

Any future updates will be listed below